Phase II Study of TAS-106 to Treat Head and Neck Cancer

Stopped early · Phase 2

Conditions studied: Head and Neck Cancer

In brief

The purpose of this study is to determine whether TAS-106 is effective to patients with recurrent or metastatic head and neck cancer refractory to platinum based chemotherapy.

Key facts

Study ID

NCT00737360

Run by

Taiho Pharmaceutical Co., Ltd.

People needed

27

Starts

2008-08-01

Expected to finish

2012-02-01

Last updated by the study team

2012-09-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 ≤ years old at study entry
• Histologically confirmed head and neck carcinoma
• Received prior platinum based regimen and developed disease progression or recurrence
• Measurable disease according to RECIST guidelines

You may not qualify if…

• Radiological or clinical evidence of brain involvement or leptomeningeal disease
• ≥ grade 2 peripheral neuropathy
• History of another malignancy

Where it is running

• Johns Hopkins Sidney Kimmel Comprehensive Cancer Center — Orleans Street, Baltimore, Maryland, United States
• University of Texas MD Anderson Cancer Center — Houston, Texas, United States
• The Chinese University of Hong Kong, Prince of Wales Hospital — Shatin, Hksar, Hong Kong
• National University Hospital — Lower Kent Ridge Road, Singapore
• National Taiwan University Hospital Department of Oncology — No. 1, Chang-De Street , Taipei, Taiwan

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.